We are focused on bettering lives

Joe has overall responsibility for the day-to-day operations of POINT. Prior to this role, Joe held various roles of increasing responsibility at the Centre for Probe Development and Commercialization (CPDC), most recently as Chief Executive Officer and President, where he led the formation and growth of the company’s contract development and manufacturing operations and the build-out of radiopharmaceutical manufacturing facilities. Prior to joining CPDC, Joe was a Scientist in Pharmaceutical Development at GlaxoSmithKline, responsible for developing products across all stages of clinical development.

Joe has a Ph.D. in biochemistry from McMaster University.

Bill is responsible for all planning, implementation, management and operation of all the financial activities of POINT. Previously a senior partner at EY, Bill has over 37 years of professional experience involving a wide range of high-growth companies in the pharmaceutical, manufacturing, and technology sectors, including private and publicly traded Canadian and US NASDAQ listed companies.

Justyna brings 11 years of radiopharmaceutical experience from the Centre for Probe Development and Commercialization (CPDC), where she led microbiology and sterility assurance programs, supported the build-out of clinical-stage GMP manufacturing facilities, and managed several internal and Client radiopharmaceutical development programs. Justyna has expertise in working with a variety of medical isotopes, including sourcing, supply chain, development and manufacturing, and application to radiopharmaceutical manufacturing. Justyna has an MSc. in biochemistry from McMaster University.

Neil graduated with a medical degree from the University of Toronto in 1988. He completed specialty training in urologic surgery and oncology from 1993 to 1996, received a Master’s in Public Health in epidemiology from Columbia University in 1997, and completed his oncology training at Memorial Sloan-Kettering Cancer Center.

Neil is certified in both urology and epidemiology. Neil is also a Professor of Surgery at the University of Toronto. In the past, he has served as the Head of the Division of Urology at the University Health Network, and the Head of Genitourinary Cancer Site group at the Princess Margaret Hospital. He also holds the prestigious Love Chair in prostate cancer prevention at Princess Margaret Hospital.

Ari is responsible for ensuring POINT remains a leader in its industry by operating efficiently and successfully executing its business strategy. In addition to acting as a representative of the CEO in business strategy and operations, Ari's organizational structure includes people and culture, corporate affairs, investor relations, communications strategy as well as technology systems. Previously, Ari was a successful entrepreneur and professional investor for over a decade, having successfully built and exited multiple technology-focused companies. Ari holds an HBA from the Ivey Business School at Western University.

Jessica brings over 15 years of experience developing early and late-stage oncology drugs. She joins POINT from Progenics Pharmaceuticals where she served as SVP clinical development advancing their PSMA targeted diagnostic and radiotherapeutic portfolio in prostate cancer and their radiotherapeutic neuroendocrine program which led to the approval of AZEDRA®. Previously, Jessica advanced global immunotherapy programs at the Ludwig Institute for Cancer Research, an orphan drug program at Gentium SpA, now Jazz Pharmaceuticals, and supported the development of a CRO business unit at US Oncology. She has expertise in study design and execution, has directly led regulatory agency communications and FDA inspections, and the clinical submission of several INDs and NDAs. Jessica started her career in the pharmaceutical industry as a Statistical Programmer and Biostatistician after receiving a Master of Public Health in Epidemiology & Biostatistics at George Washington University.

As the Executive Vice President of Regulatory Affairs, Myra brings over 27 years of experience in the pharmaceutical industry in areas such as regulatory affairs and product development. In her previous role, Myra served as Vice Present Regulatory Affairs GlycoMimetics. Prior to GlycoMimetics, she served as Senior Director, Oncology Global Regulatory Affairs at AbbVie. She has broad experience in Regulatory, Protocol Review, Clinical Development and Biomarkers gained during her tenure at 18 years at Novartis and Glaxo Wellcome/GlaxoSmithKline. Myra holds a Ph.D. in Microbiology and Immunology from the University of Oklahoma Health Sciences Center, completed a post-doctoral fellowship in molecular biology NIH and is a licensed pharmacist.

Mr. Horvath began his career as a scientist, working at both DuPont and Novartis Institutes for BioMedical Research. He then transitioned to commercial roles of increasing responsibility at Janssen, Dendreon, Merck, Bayer, and most recently Advanced Accelerator Applications (Novartis). Mr. Horvath holds a BSc in Chemistry & Biology from Wilfrid Laurier University, a MSc in Analytical Science from the University of Guelph, and an MBA from Rutgers Business School.

Matt leads business development activities for POINT. He brings more than 25 years of pharma business development experience through a variety of partnering, licensing, and M&A transactions including strategic partnerships and acquisitions involving Pfizer, GSK, BMS, Merck, Genentech/Roche, Moderna and Astellas, as well as several Asian life science companies. He earned a PhD in Biochemistry from Tufts University School of Medicine as well as a JD from Suffolk University School of Law, and he is also a co-inventor on several patents directed to near-clinical drug moieties.

Melita Ann Sequeira is a dedicated HR professional with more than 20 years of diverse human resources management experience, working in a variety of organizations from start-ups and established organizations. She possesses experience in several aspects of human resources including talent management, talent acquisition, change management, coaching, workforce planning, employee engagement, employee relations, benefits and compensation.

Valerie is responsible for the management of POINT’s early and late-stage clinical development and manufacturing programs.  She brings 16 years of experience in the radiopharmaceutical manufacturing space, working with imaging and therapeutic products at Lantheus Medical Imaging (5 years) and the Centre for Probe Development and Commercialization (11 years). In Valerie’s most recent role as the Director of Radiopharmaceutical Development & Supply at CPDC, she was responsible for development, validation and supply of numerous early and late-phase clinical alpha and beta-emitting products. Valerie has a BSc. in Biotechnology from Brock University.

Sherin is responsible for medical affairs at POINT. Previously, she was the Global Medical Affairs Oncology Strategy Director at Bayer, where she developed and executed the medical strategy for the prostate cancer franchise, including the radiopharmaceutical Xofigo®. Dr. Al-Safadi graduated with an MSc in Pharmacology and Therapeutics from McGill University and earned her PhD in Neurobiology from Concordia University following her MBA in Entrepreneurship and Management at the John Molson School of Business.

Robin is responsible for preclinical development at POINT. He is an experienced leader in drug discovery and development with broad expertise from early discovery through to first-in-human studies. Previously, Robin was Head of Translational Sciences at Northern Biologics, which focused on developing first-in-class biologics for the treatment of solid tumours. Robin obtained his Ph.D. in biochemistry from McMaster University and completed post-doctoral training at the Hospital for Sick Children in cancer biology.